AUGM-101
/ 1E Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 15, 2021
In This Study AUGM-101 Will be Assessed for Its Safety, Tolerability, Pharmacokinetic and Pharmacodynamic in Healthy Volunteers and COVID-19-infected Patients
(clinicaltrials.gov)
- P1/2; N=104; Recruiting; Sponsor: 1E Therapeutics
Clinical • New P1/2 trial • Infectious Disease • Novel Coronavirus Disease
1 to 1
Of
1
Go to page
1